Basiliximab

Drug #813

Basiliximab is a chimeric murine monoclonal anti-interleukin-2 receptor (CD25) antibody.Basiliximab is used in conjuntion with other immunosuppressant drugs in patients undergoing organ transplantation to prevent graft rejection.

← Previous drug Next drug →

Primary Characteristics

It is of Semi Synthetic origin and belongs to Protein.

It is classified in Monoclonal Antibody pharmacological group. It is also classified under CDC Biologicals .

Solubility in Water: null · Solubility in Alcohol: null · Non-proprietary name: Basiliximab.

Pharmacokinetics

Distribution: Basiliximab has a volume of distribution is 5.2 ± 2.8 litre (children), 8.6 litre (adult).

Elimination: it is metabolised via 20 ml/hr (children), 41 ml/hr (adult), plasma half-life is 9.4 days (children), 7.2 days (adult).

Indications

Basiliximab is primarily indicated in conditions like Organ transplantation, Prophylaxis of acute graft rejection episodes, Prophylaxis of acute rejection in allogenic renal transplantation.

Contraindications

Basiliximab is contraindicated in conditions like Hypersensitivity, Pregnancy, Breast feeding.

Dosage

Basiliximab's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
20 mg	20 mg	—	IV Inf	665 ug/min For 30 minutes, repeat after 4 days, as required.
Paediatric Dosage (20kg)
12 mg/sq.meter	12 mg/sq.meter	—	IV Infusion	Over20-30 minutes, repeate after 4 days
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

None recorded.

Side Effects

Basiliximab in overdosage may give rise to further complications which include Hypertension , Urinary tract infection .

Basiliximab is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Constipation , Cough , Dizziness, Dyspepsia , Dyspnea, Dysuria, Fatigue, Fever, Headache, Insomnia, Nausea, Pain , Peripheral edema, Rhinitis , Tremor, Weight gain.

Warnings / Precautions

Basiliximab is not recommended for use during pregnancy or lactation. Immunosuppressant drug should not be given, where possible, to patients with acute infection, dosage reduction or withdrawal should be considered if infection develops, until the infection has been controlled. Blood counts and measurement of hemoglobin concentration should be carried out routinely, help to predict the onset of bone marrow depression. It must be handled with great care and avoid contact with skin and eyes and should not be inhaled.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

20 mg/vial

Storage Conditions

Basiliximab should be stored Inj.

Drug Classification

1.8.1 — Immunomodulators

Manufacturers

Manufacturers of Basiliximab in Pakistan:

Novartis